|
|
|
|
Cytokinetics Incorporated (CYTK) |
|
|
|
| |
Cytokinetics Incorporated's Quick Ratio
CYTK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth
In the wake of the increase in Current Liabilities in the third quarter 2023, Quick Ratio fell to 8.91 above Cytokinetics Incorporated average.
Within Major Pharmaceutical Preparations industry 71 other companies have achieved higher Quick Ratio than Cytokinetics Incorporated in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 88 to 225.
Explain Quick Ratio?
How much Cash & cash equivalents CYTK´s has?
What are CYTK´s Current Liabilities?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| CYTK Quick Ratio |
(Sep 30 2023)
III. Quarter |
(Jun 30 2023)
II. Quarter |
(Mar 31 2023)
I. Quarter |
(Dec 31 2022)
IV. Quarter |
(Sep 30 2022)
III. Quarter |
| Y / Y Current Liabilities Change |
0.08 % |
-4.99 % |
16.43 % |
25.95 % |
-10.17 % |
| Y / Y Cash & cash equivalent Change |
-37.85 % |
-3.46 % |
9.03 % |
65.93 % |
81.66 % |
| Quick Ratio MRQ |
8.91 |
11.33 |
10.89 |
10.9 |
14.36 |
| CYTK's Total
Ranking |
# 225 |
# 88 |
# 103 |
# 113 |
# 270 |
| Seq. Current Liabilities Change |
21.18 % |
-18.11 % |
-15.09 % |
18.78 % |
15.04 % |
| Seq. Cash & cash equivalent Change |
-4.68 % |
-14.8 % |
-15.16 % |
-9.81 % |
48.06 % |
| Quick Ratio third quarter 2023 Company Ranking |
| Within: |
No. |
| Major Pharmaceutical Preparations Industry |
# 72 |
| Healthcare Sector |
# 123 |
| Overall Market |
# 225 |
| Quick Ratio Statistics |
| High |
Average |
Low |
| 22.68 |
8.87 |
1.81 |
| (Jun 30 2012) |
|
(Sep 30 2013) |
Cumulative Cytokinetics Incorporated's Quick Ratio
CYTK's Quick Ratio for the trailling 12 Months
CYTK Quick Ratio |
(Sep 30 2023)
III. Quarter |
(Jun 30 2023)
II. Quarter |
(Mar 31 2023)
I. Quarter |
(Dec 31 2022)
IV. Quarter |
(Sep 30 2022)
III. Quarter |
| Y / Y Current Liabilities TTM Growth |
0.08 % |
-4.99 % |
16.43 % |
25.95 % |
-10.17 % |
| Y / Y Cash & cash equivalent TTM Growth |
-37.85 % |
-3.46 % |
9.03 % |
65.93 % |
81.66 % |
| Quick Ratio TTM |
10.49 |
11.85 |
11.8 |
12 |
11.4 |
| Total
Ranking TTM |
# 250
| # 3194
| # 2186
| # 3197
| # 372
|
| Seq. Current Liabilities TTM Growth |
21.18 % |
-18.11 % |
-15.09 % |
18.78 % |
15.04 % |
| Seq. Cash & cash equivalent TTM Growth |
-4.68 % |
-14.8 % |
-15.16 % |
-9.81 % |
48.06 % |
On the trailing twelve months basis Due to growth in Current Liabilities in the III Quarter 2023 to $60.49 millions, cumulative Quick Ratio decreased to 10.49 above the CYTK average Quick Ratio. Quick Ratio is the average cumulative value over the last four quarters.
Among companies operating within Major Pharmaceutical Preparations industry 116 other companies have achieved higher Quick Ratio than Cytokinetics Incorporated. While Quick Ratio overall ranking has improved so far to 250, from total ranking during the twelve months ending second quarter 2023 at 3194.
Explain Quick Ratio?
How much Cash & cash equivalents CYTK´s has?
What are CYTK´s Current Liabilities?
| TTM Quick Ratio Company Ranking |
| Within: |
No. |
| Within the Major Pharmaceutical Preparations Industry |
# 117 |
| Healthcare Sector |
# 181 |
| Within the Market |
# 250 |
| trailing twelve months Quick Ratio Statistics |
| High |
Average |
Low |
| 12.89 |
6.92 |
2.53 |
| (Mar 31 2021) |
|
(March 31, 2014) |
|
Date modified: 2023-11-06T19:11:58+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
